LEO’s Adbry demonstrates long-term efficacy in atopic dermatitis
The Phase III ECZTEND study reported that patients treated with Adbry demonstrated long term safety and efficacy for up to six years.
The Phase III ECZTEND study reported that patients treated with Adbry demonstrated long term safety and efficacy for up to six years.
What's Your Reaction?
